` MGX (Metagenomi Inc) vs S&P 500 Comparison - Alpha Spread

M
MGX
vs
S&P 500

Over the past 12 months, MGX has underperformed S&P 500, delivering a return of -53% compared to the S&P 500's +13% growth.

Stocks Performance
MGX vs S&P 500

Loading
MGX
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
MGX vs S&P 500

Loading
MGX
S&P 500
Difference
www.alphaspread.com

Performance By Year
MGX vs S&P 500

Loading
MGX
S&P 500
Add Stock

Competitors Performance
Metagenomi Inc vs Peers

S&P 500
MGX
ABBV
AMGN
GILD
VRTX
Add Stock

Metagenomi Inc
Glance View

Market Cap
81.1m USD
Industry
Biotechnology

Metagenomi Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Emeryville, California and currently employs 223 full-time employees. The company went IPO on 2024-02-09. Metagenomi, Inc. is a precision genetic medicine company. The firm is focused on developing curative therapeutics for patients using its comprehensive metagenomics derived toolbox. Its diverse and modular genome editing toolbox is designed to precisely target any site in the human genome. Its comprehensive genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, including prime editing systems and clustered regularly interspaced short palindromic repeat (CRISPR)-associated transposases (CASTs). The company has also developed an expansive and modular toolbox of genome editing systems that will allow it to interact with the human genome in a site-specific manner, where each tool can be matched to specific disease targets. Its platform enables it to rapidly and effectively find, screen, and select tools with the highest targetability, specificity, and efficiency in order to develop them into genetic medicine.

MGX Intrinsic Value
0.8 USD
Overvaluation 63%
Intrinsic Value
Price
M
Back to Top